Biocon Agrees Biosimilar Partnership With Evotec
The Two Firms Have Signed A Licensing Deal
Biocon and Evotec have struck a licensing deal that will allow Biocon to expand its current basket of biosimilars beyond diabetes, oncology and immunology, in exchange for licensing and milestone payments to Evotec.
You may also be interested in...
Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.
Cipla has partnered with mAbxience to supply oncology and respiratory-related biosimilars on the WHO model list of essential medicines to South Africa.